Fig. 1

upregulated LINC00152 is associated with EC cell resistance to L-OHP. a the expression of LINC00152 in EC tissues and normal adjacent tissues detected by RT-qPCR assay. * p < 0.05 vs. normal adjacent tissues (analyzed by paired t-test). b the expression of LINC00152 in Kyse-30, Kyse-70, Kyse-150, TE-1 and TE-6 cell lines detected by RT-qPCR assay. * p < 0.05 vs. Het-1A cells (analyzed by one-way ANOVA with Tukey’s post hoc test). c cell survival rate after 72 h of treatment with different doses of L-OHP (0, 0.5, 1.0, 2.5, 5.0, 10.0 µM) detected by CCK-8 assay. d cell survival rate after 0, 24, 48 and 72 h of treatment with 10.0 µM of L-OHP detected by CCK-8 assay. e, the expression of LINC00152 after 0, 24, 48 and 72 h of treatment with 10.0 µM of L-OHP detected by RT-qPCR assay. * indicates p < 0.05 when Kyse-150 vs.Kyse-30, Kyse-70, and TE-6, respectively; # p < 0.05 when TE-1 vs. Kyse-30, Kyse-70, and TE-6, respectively (analyzed by one-way ANOVA with Tukey’s post hoc test or repeated measures ANOVA with Bonferroni corrections). f–i, Western blot analysis of E-cadherin, vimentin, cleaved PARP, and cleaved Caspase 3 in five EC cells with or without after 72-hour treatment of 10.0 µM L-OHP. * indicates p < 0.05 vs. parental or L-OHP-treated Kyse-30, Kyse-70, and TE-6, respectively; # indicates p < 0.05 vs. corresponding parental EC cells (analyzed by one-way ANOVA with Tukey’s post hoc test or repeated measures ANOVA with Bonferroni corrections). Data are presented as mean ± standard deviation of three technical replicates